Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Recruiting

Phase 2

BIIB122Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Sponsor:

Denali Therapeutics Inc.

Code:

NCT06602193

Conditions

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 30+

Healthy Volunteers: Not accepted

Interventions

BIIB122 225 mg

BIIB122-Matching Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-27. This information was provided to ClinicalTrials.gov by Denali Therapeutics Inc. on 2025-11-28.